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Aspirin and air travellers 
To the Editor: In an article in Update, a journal for general 
practitioners, Singh et al.1 state that ‘subcutaneous heparin and 
low-dose aspirin have been recommended as risk-reducing 
agents for air-travellers at known risk for DVT’. (It is unclear 
whether this implies heparin and low-dose aspirin or heparin 
or low-dose aspirin.) However, in an SAMJ article entitled ‘The 
BEST Study – a prospective study to compare business class 
versus economy class air-travel as a cause for thrombosis’, 
Barry Jacobson et al.2 state that the New Zealand Air Traveller’s 
Thrombosis (NZATT) study has now reported that ‘aspirin 
does not prevent travel-associated venous thrombosis’. This 
latter opinion seems a rational one in light of the fact that 
aspirin reduces platelet aggregation in arteriosclerotic plaques.
General practitioners are frequently consulted by prospective 
air travellers as to whether they should use aspirin before and 
during a flight. The issue is clearly controversial, and it would 
be helpful to establish consensus. I am accordingly submitting 
this letter to SAMJ, which enjoys a multidisciplinary and 
academic readership, hoping to solicit such consensus through 
these columns.
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Huntington’s disease-like 2 in South 
Africa
To the Editor: Huntington’s disease (HD) is a late onset, 
autosomal dominant neurodegenerative disorder characterised 
by progressive movement impairment, affective disturbance 
and cognitive dysfunction. In 2001, Huntington’s disease-like 2 
(HDL2) was identified.1 The causative factor in both disorders 
is due to a repeat expansion mutation but these occur in two 
distinct genes: the IT15 gene (chromosome 4p16.3) for HD and 
the JPH3 gene (chromosome 16q24.3) for HDL2.
In a recent pilot study, 63 individuals of either black African 
(BA) or coloured ancestry (also referred to as mixed ancestry 
– MA) who were previously found not to carry the HD-causing 
expansion following routine testing by the University of Cape 
Town (UCT)’s National Health Laboratory Services (NHLS) 
laboratory, were screened for the HDL2 disease-causing 
expansion. Eight individuals from 4 families were found to 
have the CTG-repeat expansion, ranging in size from 41 to 
60 repeats. Three of these families were of BA origin and one 
was an MA family.2 In our preliminary haplotype studies to 
ascertain the origin of the HDL2 mutation, a common core 
haplotype was inferred for the BA and MA groups.
The aim of this letter is to raise awareness among clinicians 
and neurologists in South Africa that HDL2 is present in the 
South African population. Interestingly, in contrast with HD 
which is found predominantly in Caucasian individuals, HDL2 
has been found worldwide exclusively in individuals of BA 
ancestry.3 The current perception is that HDL2 should only 
be considered in individuals whose recent ancestors are of 
BA descent, but we have shown that in South Africa it is also 
present in the MA population, and could therefore be missed. 
Awareness should therefore be raised that HDL2 should not 
only be considered in BA individuals.
It is also clear from the literature and from our experience 
that many HDL2 patients do not manifest with chorea, but 
present with variants of a rigid-akinetic syndrome.4 Similarly, 
MRI features may be atypical when compared with HD, with 
greater evidence for damage to the striatum in HDL2.
We therefore propose that a diagnosis of HDL2 should 
be considered in a wide spectrum of neuropsychiatric and 
abnormal movement presentations. A molecular diagnostic test 
for HD and HDL2 is now available to test simultaneously for 
both conditions at the UCT NHLS laboratory. It is anticipated 
that identification of more HDL2 patients from diverse 
populations will broaden the phenotypic description of this 
apparently rare disorder.
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